GSK · story · 12 November – 13 November
GSK · 5 headlines from 5 outlets, from 12 November 2026 to 13 November 2026.
GSK won a broad European injunction in its vaccine patent dispute with Pfizer and BioNTech.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
Yahoo Finance is the largest at 10.0, ahead of IAM Patent (10.0). JUVE Patent is the smallest at 5.0.
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| Yahoo Finance | 10.0 |
| IAM Patent | 10.0 |
| Life Sciences IP Review | 9.2 |
| Law360 | 9.2 |
| JUVE Patent | 5.0 |
| Outlet | Headlines | Average tone |
|---|---|---|
| Yahoo Finance | 1 | +10.0 |
| IAM Patent | 1 | +10.0 |
| Life Sciences IP Review | 1 | +9.2 |
| Law360 | 1 | +9.2 |
| JUVE Patent | 1 | +5.0 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +10.0 | Patent dispute resolved with wide-reaching injunction in company's favour |
| +9.2 | Won injunction covering many countries in vaccine litigation |
| +5.0 | Only partly successful outcome in patent court dispute |
| Tone | What the article reported, and why it scored that way |
|---|---|
| +10.0 | Injunction covering many countries strengthens its patent position against rivals. |
| +9.2 | Won patent ruling against two major vaccine rivals. |
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.